Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 17/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 17/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4729558 | 0.84 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL4730581 | 0.84 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL4729805 | 0.84 | HDAC6 (0.75) | HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL3698385 | 0.83 | HDAC6 (1.00) | HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL4729486 | 0.83 | HDAC6 (1.00) | HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL4730090 | 0.82 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL4729588 | 0.80 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL4729545 | 0.79 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL4729803 | 0.79 | HDAC1 (0.80) | HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL4730016 | 0.78 | HDAC3 (1.00) | HDAC1HDAC6HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170096403-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS, INC. | 2017-04-06 | — | — | US | disclosed |
| EP-3067346-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | Acetylon Pharmaceuticals, Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| US-9409890-B2 | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof | ACETYLON PHARAMCEUTICALS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20140142104-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS, INC. | 2014-05-22 | — | — | US | disclosed |
| WO-2012068109-A2 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120121502-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142104-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC5 | HDAC1 2/4885HDAC6 1/4885HDAC3 8/4885 |
| US-20120121502-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC5 | HDAC1 2/4885HDAC6 1/4885HDAC3 8/4885 |
| US-20170096403-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC5 | HDAC1 2/4885HDAC6 1/4885HDAC3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.